Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemiaXin Huang, Jun J. Yang|Cancer Cell|2024Cited by 31
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemiaXujie Zhao, Jun J. Yang, Jingliao Zhang et al.|Nature Communications|2022Cited by 27
Differentiation-dependent EBF1 activity determines <i>CD22</i> transcription and leukemia sensitivity to inotuzumab ozogamicinCarolin S. Escherich, Jun Yang, Zhenhua Li et al.|Blood|2025Cited by 5